Introduciton
tumor, cancer death, Lung cancer, cancer deaths, human lung adenocarcinoma
LUNG CANCER, TUMOR GROWTH, TUMOR
Lung cancer remains the leading cause of cancer death globally, accounting for approximately one in five (18.0%) of the total cancer deaths,Several pivotal trials, including the METROS trial,Unecritinib (TQ-B3101), a multi-TKI targeting ROS1, ALK, and c-MET, is a derivative of crizotinib Meanwhile, our preclinical studies showed a greater bioavailability of unecritinib than crizotinib in beagles (data not published). In mouse xenografts bearing human lung adenocarcinoma NCI-H3122 cells, unecritinib showed greater tumor growth inhibition than crizotinib, which may be explained by higher tumor tissue exposure to unecritinib In this phase I/II study, we aimed to characterize the tolerability, safety, and antitumor activities of unecritinib in ROS1 inhibitor-naive patients with 